To identify women at increased risk of developing breast cancer, the National Comprehensive Cancer Network and the American Society of Clinical Oncology both recommend complete mutation screening of ATM, CDH1, CHEK2, PALB2, PTEN, STK11 and TP53 in addition to BRCA1/2 genes. This evidence concerns the gene CHEK2 and breast carcinoma.